🔎 Trials Near Me

Domov › Akútna biphenotypová leukémia › New York

Klinické štúdie Akútna biphenotypová leukémia v štáte New York

11 štúdií pre Akútna biphenotypová leukémia hľadá účastníkov v zariadeniach v štáte New York.

Mestá v štáte New York

Oficiálny text štúdie (anglicky)

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • Memorial Sloan Kettering Cancer Center, New York
Prebieha náborFáza 1
Vek 12 až 78 · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT03802695

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Albany Medical Center, Albany
  • Roswell Park Cancer Institute, Buffalo
  • The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
  • a 7 ďalších
Prebieha náborFáza 2
365 Days · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06317662

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Montefiore Medical Center, New York
Prebieha náborFáza 1/2
30 Days · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT04065399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Albany Medical Center, Albany
  • Maimonides Medical Center, Brooklyn
  • Roswell Park Cancer Institute, Buffalo
  • a 12 ďalších
Prebieha náborFáza 3
365 Days – 25 Years · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Albany Medical Center, Albany
  • Maimonides Medical Center, Brooklyn
  • NYU Langone Hospital - Long Island, Mineola
  • a 7 ďalších
Prebieha náborFáza 1/2
Do veku 22 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04726241

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • New York Medical College, Valhalla
Prebieha náborFáza 1/2
Vek 13 až 90 · Všetky pohlavia · Aktualizované 6. 8. 2026 · NCT06533579

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • Memorial Sloan- Kettering Cancer Center, New York
Prebieha náborFáza 1
Vek 1 až 30 · Všetky pohlavia · Aktualizované 3. 8. 2026 · NCT06177067

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Weill Cornell Medicine - New York Presbyterian Hospital, New York
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 7. 7. 2026 · NCT07216443

A Study of Revumenib and Mezigdomide in People With Leukemia

  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
  • a 1 ďalších
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 22. 6. 2026 · NCT07356154

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

  • Memorial Sloan Kettering Cancer Center, New York
Prebieha náborFáza 1
Vek 12 a viac · Všetky pohlavia · Aktualizované 8. 1. 2026 · NCT04872478

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Hospital New York-Presbyterian, New York
  • Memorial Sloan Kettering Cancer Center, New York
Prebieha náborFáza 1
Vek 1 až 21 · Všetky pohlavia · Aktualizované 6. 12. 2024 · NCT05476770

Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.